{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:04:01Z","timestamp":1791849841821,"version":"4.3.4"},"reference-count":18,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,10,1]]},"abstract":"<jats:p>We investigated the effect of alendronate on calcium, PTH, and bone mineral density in 27 female and 5 male patients with primary hyperparathyroidism. The treatment group [n = 14; T score \u2264 \u22122.5 sd at the femoral neck (FN) or T \u2264 \u22121.0 sd plus previous nonvertebral fracture] was given alendronate 10 mg\/d for 24 months. The second group (n = 18; T score &amp;gt; \u22122.5 sd at the FN) was untreated. Biochemistry was repeated at 1.5, 3, 6, 12, 18, and 24 months, and dual-energy x-ray absorptiometry at 12 and 24 months.<\/jats:p><jats:p>There were no significant between-group baseline differences in calcium, creatinine, or PTH. Alendronate-treated patients gained bone at all sites [lumbar spine (LS), 1 yr gain, +7.3 \u00b1 1.7%; P &amp;lt; 0.001; 2 yr, +7.3 \u00b1 3.1%; P = 0.04). Untreated patients gained bone at the LS over 2 yr (+4.0 \u00b1 1.8%; P = 0.03) but lost bone elsewhere. Calcium fell nonsignificantly in the alendronate group between baseline (2.84 \u00b1 0.12 mmol\/liter) and 6 wk (2.76 \u00b1 0.09 mmol\/liter), with a nonsignificant rise in PTH (baseline, 103.5 \u00b1 14.6 ng\/liter; 6 wk, 116.7 \u00b1 15.6 ng\/liter). By 3 months, values had reverted to baseline.<\/jats:p><jats:p>In primary hyperparathyroidism, alendronate is well tolerated and significantly improves bone mineral density at the LS (with lesser gains at FN and radius), especially within the first year of treatment. Short-term changes in calcium and PTH resolve by 3 months.<\/jats:p>","DOI":"10.1210\/jc.2001-010385","type":"journal-article","created":{"date-parts":[[2002,10,3]],"date-time":"2002-10-03T19:06:01Z","timestamp":1033671961000},"page":"4482-4489","source":"Crossref","is-referenced-by-count":103,"title":["Alendronate in the Treatment of Primary Hyperparathyroid-Related Osteoporosis: A 2-Year Study"],"prefix":"10.1210","volume":"87","author":[{"given":"C. R.","family":"Parker","sequence":"first","affiliation":[{"name":"Division of Mineral Metabolism (C.R.P., D.J.H.), Nottingham NG5 1PB, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"Blackwell","sequence":"additional","affiliation":[{"name":"Departments of Clinical Chemistry (P.J.B.), Nottingham NG5 1PB, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. J.","family":"Fairbairn","sequence":"additional","affiliation":[{"name":"Radiology (K.J.F.), City Hospital, Nottingham NG5 1PB, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Hosking","sequence":"additional","affiliation":[{"name":"Division of Mineral Metabolism (C.R.P., D.J.H.), Nottingham NG5 1PB, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071618513278000_R1","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM198606053142304","article-title":"Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women.","volume":"314","author":"Selby","year":"1986","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2020071618513278000_R2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s002239900170","article-title":"The correlation of bone mineral density and biochemical markers to fracture risk","volume":"59","author":"Adachi","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"2020071618513278000_R3","first-page":"3487","article-title":"Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.","volume":"81","author":"Guo","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618513278000_R4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2265.1990.tb00869.x","article-title":"Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status.","volume":"32","author":"Schmidli","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071618513278000_R5","first-page":"1067","article-title":"Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate.","volume":"77","author":"Reasner","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618513278000_R6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","article-title":"Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.","volume":"16","author":"Rossini","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2020071618513278000_R7","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/oxfordjournals.aje.a115204","article-title":"Epidemiology of vertebral fractures in women.","volume":"129","author":"Melton","year":"1989","journal-title":"Am J Epidemiol"},{"key":"2020071618513278000_R8","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/jbmr.5650061425","article-title":"Characterization and evaluation of asymptomatic primary hyperparathyroidism","author":"Bilezikian","year":"1991","journal-title":"J Bone Miner Res 6(Suppl 2):S85\u2013S89; discussion,"},{"key":"2020071618513278000_R9","first-page":"S121","article-title":"Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention","author":"Parfitt","year":"1991","journal-title":"J Bone Miner Res 6(Suppl 2):S97\u2013S101; discussion,"},{"key":"2020071618513278000_R10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2020071618513278000_R11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9343(93)90350-X","article-title":"Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.","volume":"95","author":"Harris","year":"1993","journal-title":"Am J Med"},{"key":"2020071618513278000_R12","first-page":"1595","article-title":"Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.","volume":"79","author":"Reid","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618513278000_R13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"2020071618513278000_R14","first-page":"690","article-title":"Anabolic actions of parathyroid hormone on bone.","volume":"14","author":"Dempster","year":"1993","journal-title":"Endocr Rev"},{"key":"2020071618513278000_R15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1210\/jcem-70-4-930","article-title":"The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure.","volume":"70","author":"Parisien","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618513278000_R16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-95-1-23","article-title":"Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism.","volume":"95","author":"Shane","year":"1981","journal-title":"Ann Intern Med"},{"key":"2020071618513278000_R17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/17453679509157686","article-title":"Collagen crosslinks in metabolic bone disease.","volume":"66","author":"Robins","year":"1995","journal-title":"Acta Orthop Scand"},{"key":"2020071618513278000_R18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jbmr.5650100418","article-title":"Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.","volume":"10","author":"Garnero","year":"1995","journal-title":"J Bone Miner Res"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/87\/10\/4482\/9155043\/jcem4482.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/87\/10\/4482\/9155043\/jcem4482.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T07:21:23Z","timestamp":1733815283000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/87\/10\/4482\/2846401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,1]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2001-010385","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10,1]]}}}